The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study

References

• McKelvey E M, Gottlieb J A, Wilson H E, Haut A, Talley R W, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Krol A D, le Cessie S, Snijder S, Kluin-Nelemans J C, Kluin P M, Noordijk E M. Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003; 44: 451–458
   PubMed Web of Science ®Google Scholar
• Moller M B, Pedersen N T, Christensen B E. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004; 124: 151–159
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hermans J, Krol A D, van Groningen K, Kluin P M, Kluin-Nelemans J C, Kramer M H, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460–1463
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen M L, van Spronsen D J, Lemmens V E, Houterman S, Verheij K D, Coebergh J W. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129: 597–606
   PubMed Web of Science ®Google Scholar
• World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 2001
   Google Scholar
• Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Hryniuk W M, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8: 1935–1937
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith T L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343–346
   PubMedGoogle Scholar
• Maartense E, Hermans J, Kluin-Nelemans J C, Kluin P M, Van Deijk W A, Snijder S, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998; 9: 1219–1227
   PubMed Web of Science ®Google Scholar
• Vose J M, Armitage J O, Weisenburger D D, Bierman P J, Sorensen S, Hutchins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Vose J M, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Grogan L, Corbally N, Dervan P A, Byrne A, Carney D N. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol 1994; 5(Suppl 2)47–51
   PubMedGoogle Scholar
• Zinzani P L, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar
• Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840–3848
   PubMed Web of Science ®Google Scholar
• Bairey O, Benjamini O, Blickstein D, Elis A, Ruchlemer R. Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 2006; 17: 928–934
   PubMed Web of Science ®Google Scholar
• Moller M B, Christensen B E, Pedersen N T. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer 2003; 98: 516–521
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Federico M, Vitolo U, Zinzani P L, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783–789
   PubMed Web of Science ®Google Scholar
• Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 1989; 72: 141–149
   PubMed Web of Science ®Google Scholar
• Osby E, Askling J, Landgren O, Dickman P W, Ekbom A, Bjorkholm M. Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma. Acta Oncol 2004; 43: 297–301
   PubMed Web of Science ®Google Scholar